Amicus Therapeutics files for $86.25 million IPO

By Jennifer Chiou

New York, May 17 - Amicus Therapeutics, Inc. filed for an estimated $86.25 million initial public offering in an S-1 filing with the Securities and Exchange Commission.

Morgan Stanley is the bookrunning manager with Goldman, Sachs & Co. as joint lead manager and Pacific Growth Equities, LLC as co-manager.

Amicus Therapeutics is a biopharmaceutical company based in Cranbury, N. J., that develops small molecule, orally active pharmacological chaperones for the treatment of human genetic diseases.

The company is in phase 2 clinical studies for its lead product candidate, Amigal, for Fabry disease. The company said it intends to start phase 1 studies for AT2101 for Gaucher disease in the second half of 2006.

Amicus Therapeutics added that it plans to file an Investigational New Drug Application for AT2220 for Pompe disease.

Amicus Therapeutics said it had a $20.833 million operating loss on zero revenues for 2005, compared to an $8.528 million operating loss on zero revenues for the same period in 2004.

Proceeds will go towards the clinical development of Amigal, AT2101, AT2220, research and development for additional preclinical programs as well as general corporate purposes.

Entities affiliated with Prospect Venture Partners II, LP, New Enterprise Associates and Frazier Healthcare Ventures are the company's largest stockholders, each with 17%, followed by entities affiliated with CHL Medical Partners with 15.9% and entities affiliated with Canaan Partners with 15.5%.

The company applied to list its stock under "AMTX" on the Nasdaq National Market.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.